Institute of Oncology, Vilnius University, Lithuania.
Adv Med Sci. 2010;55(2):273-80. doi: 10.2478/v10039-010-0044-1.
To assess the survival rate of female lung cancer treated at the Institute of Oncology of the Vilnius University, Lithuania during the period between 1996-2005.
During the period between 1996-2005, 471 women diagnosed with lung cancer were treated at the Department of Thoracic Surgery and Oncology of the Institute of Oncology, Vilnius University. Data on morphology, stage and treatment was collected from the medical records. All lung cancer cases by histology were classified in two groups: non-small cell lung cancer (includes squamous cell carcinoma, large cell carcinoma, adenocarcinoma and other less common types) and small cell lung cancer. The vital status of the study group was assessed as of December 31, 2007, by passive follow-up, using data from the population registry. It was found that 411 (87.3%) of the patients had died. Survival was estimated according to the Kaplan-Meier method.
The median survival of female lung cancer diagnosed during 1996-2005 in Lithuania show to be 8.7 months (8.4 (95% CI 7.2-10.8) months with non-small cell lung cancer and 9.3 (95% CI 6.3-13.0) months with small-cell lung cancer). Survival was more than 20 months in resectable non-small cell lung cancer (stages I, II, IIIA). Non-small cell lung cancer survival in advanced stages was less than 7 months. Small-cell lung cancer patients median survival at limited and extended stages of the disease were 9.5 (95% CI 2.9-18.4) compared to 9.2 (95% CI 6.2-13.7) months. Non-small cell lung cancer patients most frequently were treated by surgery (27.0%), surgery and chemotherapy or radiotherapy (19.6%). Small cell lung cancer patient treatment included chemo and radiotherapy (27.0%), chemotherapy (19.0%), radiotherapy (17.5%), surgery (27.9%).
The single center study of female lung cancer diagnosed during 1996-2005 in Lithuania show a significantly better chance of survival in resectable non-small cell lung cancer. Advanced stages of the disease at the time of diagnosis and choice of treatment options of female lung cancer in the country still remains an issue.
评估 1996-2005 年期间在立陶宛维尔纽斯大学肿瘤研究所接受治疗的女性肺癌患者的生存率。
在 1996-2005 年期间，471 名被诊断患有肺癌的女性在维尔纽斯大学肿瘤研究所胸外科和肿瘤学系接受治疗。从病历中收集形态学、分期和治疗数据。所有经组织学诊断的肺癌病例均分为两组：非小细胞肺癌（包括鳞状细胞癌、大细胞癌、腺癌和其他较少见的类型）和小细胞肺癌。截至 2007 年 12 月 31 日，通过被动随访，使用人口登记处的数据评估研究组的存活情况。结果发现，411 名（87.3%）患者死亡。采用 Kaplan-Meier 法估计生存率。
立陶宛 1996-2005 年期间诊断的女性肺癌患者的中位生存时间为 8.7 个月（非小细胞肺癌为 8.4（95%CI 7.2-10.8）个月，小细胞肺癌为 9.3（95%CI 6.3-13.0）个月）。可切除的非小细胞肺癌（I 期、II 期、IIIA 期）的生存时间超过 20 个月。晚期非小细胞肺癌的生存时间不到 7 个月。局限性和广泛性疾病的小细胞肺癌患者的中位生存时间分别为 9.5（95%CI 2.9-18.4）个月和 9.2（95%CI 6.2-13.7）个月。非小细胞肺癌患者最常接受手术治疗（27.0%）、手术加化疗或放疗（19.6%）。小细胞肺癌患者的治疗包括化疗和放疗（27.0%）、化疗（19.0%）、放疗（17.5%）、手术（27.9%）。
立陶宛 1996-2005 年期间诊断的女性肺癌的单中心研究表明，可切除的非小细胞肺癌患者的生存机会显著提高。诊断时疾病的晚期阶段以及该国女性肺癌治疗选择仍然是一个问题。
